万孚生物(300482)7月20日晚间公告，公司近日收到国家药监局颁发的人类微卫星不稳定性（MSI）检测 试剂盒（荧光PCR熔解曲线法）的医疗器械注册证。MSI检测对多种实体瘤患者有重要意义，包括林奇 综合征筛查、指５-FU类化疗药物的选择、预后分层和筛选免疫检查点抑制剂获益人群等。 ...

证券日报网讯 万孚生物7月30日在互动平台回答投资者提问时表示，海外竞争方面，目前公司产品已经 覆盖全球超过150个国家和地区，对海外当地商业模式及政策合规有着深入的了解，且公司技术平台布 局齐全，项目丰富，可以满足当地市场需求。 （编辑 袁冠琳） ...

（编辑 袁冠琳） 证券日报网讯 万孚生物7月30日在互动平台回答投资者提问时表示，公司始终关注宠物健康领域的市场 需求，依托自身在体外诊断领域的技术积累，积极布局宠物用诊断产品。万德康现有检测平台包括免疫 荧光检测、凝血检测、血气电解质检测、生化检测、分子诊断、精子质量检测、白细胞检测、智能检测 APP"宠康康"等。"宠康康"由万孚生物首创，将传统的化验室集成虚拟至云端，以特定载体让化验室移 动起来，针对动物诊疗行业提供快速、准确、全面的检测与辅助诊断。 ...

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，公司暂无针对血铅检测 的相关产品。 ...

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，公司时刻关注呼吸道传 染病市场需求动态变化，努力为患者提供更高效、更全面的快检筛查服务，满足市场的检测需求。具体 产品销售情况请留意公司相关公告。 ...

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，多年前公司在美国圣地 亚哥布局了本地化工厂，已具备量产的能力，可随时满足当地客户的本地化生产需求。 ...

证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，研发投入方面，公司近 年来持续注重研发能力，研发投入均超过营业收入的10%，未来公司仍旧会从守好胶体金荧光基本盘， 开拓化学发光、分子、病理等新技术平台的产品研发。 ...

Core Viewpoint - The company emphasizes the significance of MSI testing for various solid tumor patients, highlighting the current limitations in clinical detection coverage due to the complexity of testing technology and high entry barriers [1] Group 1: Company Technology and Product - The company's product utilizes fluorescent PCR melting curve method, which is characterized by its widespread platform applicability, simplified process, and rapid reporting [1] - The detection time has been reduced from the existing 4-5 hours to 90 minutes, enhancing efficiency [1] - The results interpretation using the melting curve method is more intuitive and convenient compared to existing technologies [1] Group 2: Market and Promotion - The company is currently unable to predict the future market promotion situation for its products, indicating uncertainty in market acceptance and penetration [1]

Core Insights - Guangzhou Wondfo Biotech Co., Ltd. has received approval from the National Medical Products Administration and the Guangdong Provincial Medical Products Administration for nine self-developed test kits [1] - The newly approved thrombus five-item test and tumor marker test kits will provide a richer testing menu and more convenient combinations for clinical use [1] Group 1: Product Development - The thrombus five-item test, including D-Dimer, aids in the auxiliary diagnosis of thrombotic diseases, early diagnosis of DIC, monitoring of thrombolytic and anticoagulant drug efficacy, and diagnosis of vascular endothelial system damage [1] - Wondfo Biotech has launched multiple fully automated chemiluminescence immunoassay analyzers with varying throughput, catering to different application scenarios [1] Group 2: Market Position and Future Plans - The company has obtained over 150 medical device product registrations globally, covering nine major areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious disease testing [1] - Wondfo Biotech aims to continue leveraging its high-level, global R&D innovation system, focusing on technological, product, and service innovations to benefit the public [1]

Company Overview - Wanfu Biology's stock price as of July 29, 2025, is 24.12 yuan, down 0.25 yuan or 1.03% from the previous trading day [1] - The company specializes in the research, development, production, and sales of rapid diagnostic reagents and related instruments, covering areas such as infectious diseases, chronic diseases, and drug testing [1] Market Performance - The opening price on the same day was 24.37 yuan, with a high of 24.38 yuan and a low of 23.68 yuan [1] - The trading volume reached 3.92 billion yuan, with a turnover rate of 3.80% [1] Product Development - Wanfu Biology's wholly-owned subsidiary, Tianshen Medical, recently received approval for 9 self-developed test kits, including thrombosis detection and tumor marker detection reagents [1] - The company has accumulated 16 medical device registration certificates for its single-use chemiluminescence system, covering 9 major areas including cardiac markers, inflammation, and thrombosis [1] Financial Flow - On July 29, the net outflow of main funds was 21 million yuan, accounting for 0.2% of the circulating market value [1]